Pregabalin for Fibromyalgia: What the Trials Show

Pregabalin was the first drug the FDA approved specifically for fibromyalgia, in 2007, and it remains one of the three medications with the most extensive trial support for the condition. Its mechanism of action is different from duloxetine’s: where duloxetine works by boosting descending inhibition, pregabalin works by reducing excitatory signaling at the spinal cord level. Understanding this distinction matters, because it explains both why the two drugs sometimes help different patients and why combining them is mechanistically plausible [5].

How Pregabalin Works

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels on presynaptic neurons. When it binds, it reduces the influx of calcium into the nerve terminal, which in turn reduces the release of excitatory neurotransmitters, including glutamate and substance P. In a sensitized nervous system, where excitatory signaling is amplified, this dampening effect reduces the gain on pain transmission [5].

The specificity of this mechanism is worth noting. Pregabalin does not block pain signaling entirely, nor does it act as a general sedative at the receptor level, though sedation is a common side effect at clinical doses. It modulates the release of excitatory neurotransmitters at synapses where the alpha-2-delta subunit is expressed, which includes the dorsal horn of the spinal cord, where peripheral pain signals first enter the central nervous system. In a person whose dorsal horn neurons have become sensitized and are amplifying signals beyond what the peripheral input warrants, reducing excitatory neurotransmitter release is, in principle, addressing the right part of the circuit.

The distinction between pregabalin’s mechanism and duloxetine’s is clinically relevant. Duloxetine is a serotonin-norepinephrine reuptake inhibitor that works primarily by enhancing descending inhibitory pathways from the brainstem. These pathways act as a volume control on pain signals in the spinal cord: more serotonin and norepinephrine in the descending pathway means stronger inhibition of pain transmission. Pregabalin works from the other direction, reducing the excitatory input rather than boosting the inhibitory control. Both approaches aim to reduce the net pain signal reaching the brain, but they do so at different points in the circuit [6].

What the Trials Found

The pivotal trial by Crofford and colleagues randomized 529 patients to pregabalin at 150, 300, or 450 mg daily or placebo for 8 weeks [1]. The 450 mg group showed the most consistent improvement: about 29% of patients on 450 mg achieved a 50% or greater reduction in pain, compared to about 13% on placebo. The 300 mg group also showed benefit, while the 150 mg group did not consistently separate from placebo.

A larger 14-week trial by Arnold and colleagues (750 patients) confirmed the finding at 300, 450, and 600 mg doses [2]. The 450 mg dose again showed the most favorable balance between efficacy and tolerability. The 600 mg dose did not produce meaningfully better pain relief than 450 mg but did increase the rate of side effects, which is why the FDA-approved range caps at 450 mg.

The meta-analysis by Häuser and colleagues, covering multiple trials, calculated a number needed to treat of approximately 9 for a 50% pain reduction at the 450 mg dose [3]. The Cochrane review by Derry and colleagues confirmed these findings and noted that pregabalin also improved sleep and overall patient impression of change, though it did not consistently improve fatigue [4].

The sleep finding deserves attention. Sleep disruption is a core feature of fibromyalgia, and the relationship between poor sleep and central sensitization is bidirectional: poor sleep worsens sensitization, and sensitization disrupts sleep. Pregabalin’s effect on sleep quality, likely mediated by its general calming effect on excitatory neurotransmission, may contribute to its clinical benefit beyond the direct analgesic effect. A patient who sleeps better may experience reduced sensitization the following day, which means the sleep benefit and the pain benefit may be partially the same benefit, operating through the same mechanism.

It is also worth noting what the trials did not consistently show. Fatigue, one of the most disabling features of fibromyalgia for many patients, did not reliably improve with pregabalin treatment. Physical function improvements were modest. The drug’s strongest effects were on pain and sleep; its effects on the broader symptom profile of fibromyalgia were less impressive.

Putting the Numbers in Context

An NNT of 9 means that for every 9 patients treated with pregabalin, one additional patient achieves a 50% pain reduction that would not have occurred on placebo. This is a real but modest effect, comparable to duloxetine’s NNT of approximately 8 for a 30% pain reduction. It also means that the majority of patients who try pregabalin will not experience a large pain reduction from it alone.

These numbers are typical for pharmacotherapy in chronic pain conditions, and they should be interpreted in context rather than in isolation. A drug that works well for one in nine patients is not a failure; it is a drug that requires realistic expectations and, in most cases, combination with other treatment components. The clinical implication is the same as for duloxetine: pregabalin is useful for a subset of patients, but it is not sufficient as a sole treatment for most. Combination with exercise, sleep management, and psychological approaches improves outcomes beyond what medication alone achieves [6].

Side Effects

The side-effect profile of pregabalin differs meaningfully from duloxetine’s, and these differences matter for treatment selection. The most common effects in trials were:

Dizziness was reported by approximately 30-40% of patients on 450 mg, most often in the first two weeks. For many patients it attenuates with continued use, but for some it remains limiting. Somnolence affected about 20-25%, and while this can be managed by taking the larger dose at bedtime, it limits daytime function for patients who need full alertness. Weight gain occurred in approximately 10-15% of patients, with average gains of 1 to 3 kg, though some patients gained more. Peripheral edema (swelling in the feet and ankles) was reported by about 6-10% [4].

The discontinuation rate due to adverse effects in trials was approximately 20-25% at the 450 mg dose, higher than duloxetine’s 15-20%. The combination of dizziness and somnolence can be significant, particularly for patients who drive or operate machinery. Weight gain is a particular concern for long-term use, since obesity can worsen chronic pain outcomes and since many people with fibromyalgia already have limited physical activity due to pain, making weight management more difficult.

Titration matters. Starting at the full 450 mg dose produces more side effects than starting lower and increasing gradually. The standard approach is to begin at 75 mg twice daily and increase by 75-150 mg every one to two weeks, based on tolerability, until the target dose is reached or side effects become limiting.

Pregabalin vs Duloxetine

Head-to-head comparison data are limited. Both drugs have similar NNTs for meaningful pain reduction. They work through different mechanisms: duloxetine boosts descending inhibition, pregabalin reduces excitatory transmission. This mechanistic difference is why some clinicians try switching patients who do not respond to one to the other, and why combination of the two is sometimes used in practice, though the evidence for combination therapy is less robust than for either drug alone.

The choice between them often comes down to the side-effect profile that is more tolerable for the individual patient: nausea and sexual dysfunction with duloxetine versus dizziness, somnolence, and weight gain with pregabalin. A patient with significant sleep disruption may benefit from pregabalin’s sedating properties; a patient with comorbid depression may benefit from duloxetine’s antidepressant effect. These are clinical judgments, not evidence-based algorithms, because the trials to establish which patient characteristics predict response to one drug over the other have not been done [6].

What Remains Uncertain

Long-term efficacy data for pregabalin in fibromyalgia are limited: most trials ran for 8 to 14 weeks, with extension studies up to a year. Whether the effect is maintained, diminishes, or requires dose increases over longer treatment periods is not well established, and this is a significant gap given that fibromyalgia is a chronic condition requiring long-term management.

The question of whether pregabalin and duloxetine combined are meaningfully more effective than either alone has not been answered by a large, well-designed trial. Abuse potential is a clinical consideration: pregabalin is a Schedule V controlled substance in the US, and post-marketing reports have noted misuse, particularly at higher doses. The mechanism for this is likely its anxiolytic and euphoric effects at supratherapeutic doses, which are distinct from its analgesic mechanism.

Finally, biomarkers that predict individual response to pregabalin versus duloxetine do not yet exist, and treatment selection remains empirical. The current approach in clinical practice, try one medication, assess the response over several weeks, switch or add if the response is insufficient, is pragmatic but not precision medicine. Whether quantitative sensory testing, genetic markers, or other tools could guide selection is a question the research has not yet answered.

Getting support for chronic pain. Chronic pain, including fibromyalgia, is a complex medical condition that deserves proper clinical attention. A GP, rheumatologist or pain specialist can help develop a management plan. The American Chronic Pain Association (theacpa.org) and the National Fibromyalgia Association (fmaware.org) have patient resources and practitioner directories.